ERBB2 and breast cancer: There were more previous systemic treatments in patients with triple negative (median 3, range 1–7) and HER2 positive (median 3, range 2–6) BC than in patients with luminal A-like (median 1, range 0–6), luminal B-like (median 2, range 0–6), and luminal B-like, HER2-positive tumors (median 2, range 0–5, P = 0.042).